Adicet Bio — Third Quarter 2026 Earnings Summary

Adicet Bio reported third-quarter 2026 financial results showing a net loss of $18.9 million and a cash position of $100.9 million. The company announced positive Phase 1 data for prulacabtagene leucel in systemic lupus erythematosus patients, with 50% of lupus nephritis patients achieving complete renal response at 12 months. Regulatory progress includes FDA clearance of an Investigational New Drug application and Fast Track designation for ADI-212 in metastatic castration-resistant prostate cancer. Additionally, the company is advancing its in vivo CAR-T platform with the first candidate expected to enter the clinic in the second half of 2027.